Ticker:
Company: Inozyme Pharma, Inc.
Sector: Biotech / Rare Disease
Alert Published: May 16, 2025
Pre-Market Move: +178.87% to $3.96
Catalyst: Acquisition by BioMarin Pharmaceutical Inc. for $4.00 per share (all-cash)
Let’s talk about one of the cleanest, clearest biotech pops we’ve seen in recent months.
This morning – May 16, 2025 – Inozyme Pharma, Inc. (NASDAQ: INZY) lit up scanners before the market even opened. If you were tuned into the right alert systems, you probably saw it flash around $3.96, up 178.87% from the prior close of $1.42. And if you were with us at StockBurger, you got that ping early – right when it mattered.
But before we get into the price action, let’s back up and tell the full story. Because INZY isn’t just another speculative biotech name. It’s a real company with a real product – INZ-701, a Phase 3 candidate aimed at treating ENPP1 Deficiency, a rare and life-threatening genetic disorder that affects bone and blood vessel health.
The News That Moved the Market
At 8:00 AM EDT, BioMarin Pharmaceutical Inc., a heavyweight in the rare disease space, dropped a press release. They’d entered into a definitive agreement to acquire Inozyme for $4.00 per share in cash, valuing the deal at around $270 million. The transaction is expected to close in Q3 2025, subject to regulatory approvals and other closing conditions.
Boom.
Minutes later, INZY exploded in the pre-market, instantly becoming the top gainer across biotech. And rightly so – this wasn’t a maybe. This wasn’t a rumor. This was a real deal, with real money on the table.
The price action responded accordingly. By the time our alert hit inboxes and dashboards, the stock had already doubled – and it wasn’t done yet.
The Setup
Let’s break down the chart quickly:
- Previous Close (May 15): $1.42
- Pre-Market Price (May 16, 8:35 AM): $3.96
- Buyout Price: $4.00
- Volume: Elevated, with institutional interest flooding in
- Support: ~$3.90
- Resistance: Capped at $4.00 due to buyout ceiling
This was a pure event-driven trade – and one of the cleaner ones we’ve seen in a while. No fluff. No confusing filings. No shaky chart levels. Just news, speed, and precision.
About Inozyme Pharma (INZY)
For those unfamiliar, Inozyme Pharma is a clinical-stage biotech company based in Boston. Their focus? Developing enzyme replacement therapies (ERTs) for rare diseases caused by mutations in ENPP1 and ABCC6 – two proteins that regulate calcium and phosphate in the body.
Their lead candidate, INZ-701, has been in Phase 3 trials for ENPP1 Deficiency, a condition that causes arterial calcification and early mortality. There are no approved therapies for this condition right now, and INZY has been at the forefront of trying to change that.
Even though they’ve flown under the radar for most retail traders, INZY has long been on the watchlists of analysts covering rare disease pipelines. They’ve also secured orphan drug designations and partnerships that gave them scientific legitimacy – just not a lot of daily trading attention.
Until today.
The BioMarin Deal: Why It Makes Sense
For BioMarin, the acquisition is strategic. They’ve built their brand on developing and marketing treatments for ultra-rare diseases, and INZ-701 fits squarely into that mission.
They’re acquiring not just a promising drug, but a team with deep knowledge in the genetic rare disease space – and a pipeline with expansion potential.
It’s the kind of synergy that makes sense both scientifically and financially.
For Traders: Why This Alert Mattered
Now, to the traders out there: this wasn’t a momentum play. This wasn’t a penny stock pump. This was a buyout with a confirmed price ceiling, triggered by public news, backed by a large-cap acquirer, and reflected immediately in the chart.
That’s the kind of clarity we like. You knew the ceiling ($4.00). You saw the deal was confirmed. The risk? Minimal – at least compared to speculative trades. The upside? Basically captured in the first few minutes of pre-market.
If you were quick, the spread between $3.60 and $3.96 offered arbitrage opportunities. If you were late, this wasn’t the kind of trade to chase. And if you were just observing? It was a perfect case study.
The Takeaway
Not every StockBurger alert looks like INZY. Most don’t. But when they do, it’s worth studying why.
We weren’t first to guess it. We were first to spot it, as it was happening, after confirmation, and before saturation.
That’s what good alerts are about – not chasing, not hyping – but surfacing real opportunities, based on news, volume, and timing.
Final Thoughts: Stay Informed, Stay Smart
If this is your first exposure to INZY, or to how acquisition trades unfold – consider it a free lesson in real-time market behavior.
But here’s the golden rule: Do your own research. Don’t just act because a ticker is moving. Read the filing. Check the acquirer. Know the risks.
We’ll keep surfacing alerts. You keep learning from them.
Because when timing meets information, anything is possible.
Stay informed. Stay early. Stay sharp.
That’s the StockBurger edge.
Pump Radar
Stock Alerts